• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Bristol-Myers Squibb (BMY) Fully Priced As FDA Approval And $2.3b Expansion Lift Outlook?

    Simply Wall St·08/20/2026 00:30:56
    Listen to the news

    Bristol-Myers Squibb (BMY) is in focus after two related announcements. The FDA granted accelerated approval for its new multiple myeloma drug ZENBEXUS, and the company committed US$2.3b to a new Houston manufacturing campus.

    See our latest analysis for Bristol-Myers Squibb.

    These announcements arrive after a strong run for Bristol-Myers Squibb, with a 30 day share price return of 12.38% and a year to date share price return of 26.47%, while the 1 year total shareholder return is 46.82%.

    If you are looking beyond Bristol-Myers Squibb for other potential growth stories in healthcare, this is a good moment to scan the market using our focused list of 42 healthcare AI stocks

    Bristol-Myers Squibb has climbed quickly, yet the share price is only slightly above the consensus target and still sits well below some intrinsic value estimates. Is the recent move already rich, or is there more room to fair value?

    Most Popular Narrative: 7.4% Overvalued

    Bristol-Myers Squibb last closed at $67.61, compared with a most widely followed fair value estimate of $62.96 that applies a 7.11% discount rate and detailed earnings assumptions.

    Analysts are assuming Bristol-Myers Squibb's revenue will decrease by 6.2% annually over the next 3 years. Analysts assume that profit margins will increase from 15.0% today to 21.5% in 3 years time.

    Read the complete narrative.

    Want to see how falling revenue and rising margins still produce that fair value for Bristol-Myers Squibb? The narrative leans on specific earnings paths and a richer future earnings multiple. Curious which financial levers do the heavy lifting in that calculation?

    Result: Fair Value of $62.96 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Bristol-Myers Squibb still faces pressure from upcoming patent expiries and a heavier revenue decline assumption, which could easily challenge this view of overvaluation.

    Find out about the key risks to this Bristol-Myers Squibb narrative.

    Another View on Bristol-Myers Squibb Valuation

    The analyst narrative suggests Bristol-Myers Squibb is 7.4% overvalued relative to a $62.96 fair value. On a simple P/E basis, though, the stock looks cheaper. Its 14.9x P/E sits well below peers at 62.8x and below a fair ratio of 18.3x. This raises the question of whether the market might eventually re-rate the stock toward that level. Is this a genuine valuation gap or just compensation for the forecast declines in revenue and earnings?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:BMY P/E Ratio as at Aug 2026
    NYSE:BMY P/E Ratio as at Aug 2026

    Next Steps

    Mixed views on Bristol-Myers Squibb so far. If you want to move quickly and form your own judgment, weigh up the 4 key rewards and 3 important warning signs

    Looking for more investment ideas beyond Bristol-Myers Squibb?

    If Bristol-Myers Squibb is on your radar, do not stop there. The next strong opportunity could be sitting in plain sight on a focused stock list.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.